


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A compound having the following formula (I):



wherein

~~R<sup>1</sup> is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s);~~

~~R<sup>2</sup> is hydroxyamino;~~


~~R<sup>3</sup> is hydrogen or a suitable substituent;~~


~~L<sup>1</sup> is (CH<sub>2</sub>)<sub>n</sub> (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and~~

~~L<sup>2</sup> is lower alkenylene;~~

~~or a salt thereof~~

R<sup>1</sup> is an N-containing heterocyclic ring represented by the following formula:





wherein

$R^4$  is hydrogen or a group selected from the group consisting of:

- (1) lower alkyl optionally substituted with di(lower)alkylamino or hydroxy,
- (2) lower alkoxy,
- (3) aryl optionally substituted with the substituent selected from the group consisting of halogen, lower alkanoyl, lower alkylsulfonyl, lower alkoxy and di(lower)alkylamino,
- (4) lower alkanoyl,
- (5) lower alkoxy-carbonyl,
- (6) arylcarbonyl,
- (7) aryl(lower)alkoxy,
- (8) amino optionally mono- or di-substituted with substituent(s) selected from the group consisting of lower alkyl, lower alkanoyl and cycloalkyl,
- (9) halo(lower)alkyl,
- (10) aryloxy,
- (11) aryl(lower)alkyl optionally substituted with hydroxy,
- (12) carboxyl,
- (13) nitro,
- (14) cyano,
- (15) halogen,
- (16) heteroaryl,
- (17) non-aromatic heterocycle optionally substituted with lower alkyl,

(18) hydroxy,

(19) (lower)alkylsulfonylcarbamoyl and

(20) non-aromatic heterocycle carbonyl;

R<sup>5</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl, and

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each hydrogen or lower alkyl,

R<sup>9</sup> is hydrogen or a group selected from the group consisting of:

(1) lower alkyl optionally substituted with di(lower)alkylamino,

(2) aryl optionally substituted with lower alkoxy,

(3) (lower)alkoxy-carbonyl,

(4) cyano,

(5) carbamoyl optionally mono- or di-substituted with (lower)alkyl,

(6) halogen,

(7) (lower)alkyl-carbonyl,

(8) arylcarbonyl and

(9) cyclo(lower)alkyl,

R<sup>10</sup> is hydrogen or a group selected from the group consisting of:

(1) (lower)alkylcarbamoyl,

(2) di(lower)alkylcarbamoyl,

(3) aryl optionally substituted with halogen,

(4) (lower)alkoxy-carbonyl,

(5) carboxy,

(6) non-aromatic heterocycle carbonyl,

(7) halogen,

(8) (lower)alkyl optionally substituted with hydroxy, (lower)alkoxy, non-aromatic heterocycle, aryl, di(lower)alkylamino or halogen, and

(9) adamantyl;

R<sup>11</sup> is hydrogen or aryl(lower)alkyl in which the aryl portion is substituted with lower alkoxy,

R<sup>12</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl optionally substituted with halogen,

R<sup>13</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl,

R<sup>14</sup> is hydrogen or lower alkyl,

R<sup>2</sup> is hydroxyamino,

R<sup>3</sup> is hydrogen or lower alkoxy,

L<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>- (wherein n is 1 to 5) optionally substituted with one or more substituent(s) selected from the group consisting of lower alkyl(s) and aryl(lower)alkyl, and wherein one methylene may be replaced with an oxygen atom, and


L<sup>2</sup> is vinylene;

or a salt thereof.

Claim 2 (Cancelled)

Claim 3 (Currently Amended): The compound of claim [[2]] 1, wherein

R<sup>1</sup> is an N-containing condensed heterocyclic ring represented by the following formula:



wherein R<sup>4</sup> and R<sup>5</sup> are each as defined in claim [[2]] 1.

Claim 4 (Currently Amended): The compound of claim 3, wherein

R<sup>4</sup> and R<sup>5</sup> are each hydrogen,

R<sup>2</sup> is hydroxyamino,

R<sup>3</sup> is hydrogen,


L<sup>1</sup> is -CH<sub>2</sub>-, and

L<sup>2</sup> is vinylene[[],];

or a salt thereof.

Claim 5 (Currently Amended): The compound of claim [[2]] 1, wherein

R<sup>1</sup> is an N-containing heterocyclic ring represented by the following formula:



wherein R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> are each as defined in claim [[2]] 1.

Claim 6 (Currently Amended): The compound of claim 5, wherein

R<sup>9</sup> is hydrogen or aryl optionally substituted with lower alkoxy,

R<sup>10</sup> is hydrogen or aryl optionally substituted with halogen, and

R<sup>11</sup> is hydrogen,

R<sup>2</sup> is hydroxyamino,


R<sup>3</sup> is hydrogen,

L<sup>1</sup> is -CH<sub>2</sub>-, and


L<sup>2</sup> is vinylene[[,] ;

or a salt thereof.


Claim 7 (Currently Amended): A compound of the following formula:




,



,




or



;

or a salt thereof.

Claim 8 (Currently Amended): A compound having the following formula (I'):



wherein

~~$R^1$  is N-containing condensed heterocyclic ring optionally substituted with one or more suitable substituent(s);~~

~~$R^2$  is hydroxyamino;~~

~~$R^3$  is hydrogen or a suitable substituent;~~


~~$L^1$  is  $(\text{CH}_2)_n$  (wherein  $n$  is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and~~

~~$L^2$  is lower alkenylene;~~

~~or a salt thereof~~

$R^1$  is an N-containing condensed heterocyclic ring represented by the following

formula:



wherein

$R^4$  is hydrogen or a group selected from the group consisting of

(1) lower alkyl,

(2) lower alkoxy,

(3) aryl optionally substituted with the substituent selected from the group consisting of halogen, lower alkanoyl, lower alkylsulfonyl, lower alkoxy and di(lower)alkylamino,

(4) lower alkanoyl,

(5) lower alkoxy-carbonyl,

(6) arylcarbonyl,

(7) aryl(lower)alkoxy,

(8) amino optionally mono- or di-substituted with substituent(s) selected from the group consisting of lower alkyl, lower alkanoyl and cycloalkyl,

(9) halo(lower)alkyl,

(10) aryloxy,

(11) aryl(lower)alkyl optionally substituted with hydroxy,

(12) carboxyl,

(13) nitro,

(14) cyano,

(15) halogen,

(16) heteroaryl and

(17) non-aromatic heterocycle optionally substituted with lower alkyl,

R<sup>5</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl, and

R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are each hydrogen or lower alkyl,

R<sup>2</sup> is hydroxyamino,


R<sup>3</sup> is hydrogen or lower alkoxy,



L<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>- (wherein n is 1 or 2) optionally substituted with one or more substituent(s) selected from the group consisting of lower alkyl(s) and aryl(lower)alkyl, and wherein one methylene may be replaced with an oxygen atom, and  
L<sup>2</sup> is vinylene;  
or a salt thereof.

Claim 9 (Cancelled)

Claim 10 (Currently Amended): A compound having the following formula (I''):



wherein

~~R<sup>1</sup> is an N-containing condensed heterocyclic ring optionally substituted with one or more suitable substituent(s);~~

~~R<sup>2</sup> is hydroxyamino;~~


~~L<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>- (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s); and~~

~~L<sup>2</sup> is lower alkenylene;~~

~~or a salt thereof~~

wherein

R<sup>1</sup> is an N-containing condensed heterocyclic ring represented by the following formula:



wherein

R<sup>4</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl, and

R<sup>5</sup> is hydrogen or a group selected from the group consisting of lower alkyl and aryl(lower)alkyl,

R<sup>2</sup> is hydroxyamino,

L<sup>1</sup> is -(CH<sub>2</sub>)<sub>n</sub>- (wherein n is 1 or 2) optionally substituted with aryl(lower)alkyl, and

L<sup>2</sup> is vinylene;

or a salt thereof.

Claim 11 (Cancelled)

Claim 12 (Currently Amended): A composition comprising the compound of claim 1  
in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of  
claim 1.

Claim 13 (Currently Amended): A pharmaceutical composition comprising the  
compound of claim 1 in an amount effective for treating or preventing an inflammatory  
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,  
acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune  
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], ~~which comprises the compound of~~  
~~claim 1.~~

Claim 14 (Currently Amended): A pharmaceutical composition ~~containing~~  
comprising:

the compound of claim 1 as an active ingredient, in association with  
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 15 (Currently Amended): The composition of claim 14 in a form suitable for  
intravenous or intramuscular administration ~~compound of claim 1 for use as a medicament.~~

Claim 16 (Withdrawn): A method for inhibiting histone deacetylase, comprising  
using the compound of claim 1.

Claim 17 (Withdrawn): A method for treating or preventing an inflammatory  
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,  
acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune  
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an  
effective amount of the compound of claim 1 to a subject in need thereof ~~human being or an  
animal.~~

Claim 18 (Currently Amended): A commercial package comprising:  
the pharmaceutical composition of claim 13 and  
a written matter associated therewith, the written matter stating that the  
pharmaceutical composition may or should be used for treating or preventing an  
inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia,

fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]],  
an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 19 (Currently Amended): A composition comprising the compound of claim 7  
in an amount sufficient to inhibit histone deacetylase ~~inhibitor comprising the compound of~~  
~~claim 7.~~

Claim 20 (Currently Amended): A pharmaceutical composition comprising an  
amount of the compound of claim 7 effective for treating or preventing an inflammatory  
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,  
acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune  
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], ~~which comprises the compound of~~  
~~claim 7.~~

Claim 21 (Currently Amended): A pharmaceutical composition ~~containing~~  
comprising:

the compound of claim 7 as an active ingredient, in association with  
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 22 (Currently Amended): ~~The compound of claim 7~~ composition of claim 20  
in a form suitable for intravenous or intramuscular administration ~~for use as a medicament.~~

Claim 23 (Withdrawn): A method for inhibiting histone deacetylase, comprising  
using the compound of claim 7.

Claim 24 (Withdrawn): A method for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an effective amount of the compound of claim 7 to a subject in need thereof ~~human being or an animal~~.

Claim 25 (Currently Amended): A commercial package comprising:  
the pharmaceutical composition of claim 20, and  
a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 26 (Currently Amended): A composition comprising the compound of claim 8 in an amount sufficient to inhibit histone deacetylase ~~inhibitor comprising the compound of claim 8~~.

Claim 27 (Currently Amended): A pharmaceutical composition comprising the compound of claim 8 in an amount effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 8.

Claim 28 (Currently Amended): A pharmaceutical composition ~~containing~~  
comprising:

the compound of claim 8 as an active ingredient, in association with  
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 29 (Currently Amended): The composition of claim 27 in a form suitable for  
intravenous or intramuscular administration ~~compound of claim 8 for use as a medicament.~~

Claim 30 (Withdrawn): A method for inhibiting histone deacetylase, comprising  
using the compound of claim 8.

Claim 31 (Withdrawn): A method for treating or preventing an inflammatory  
disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis,  
acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune  
disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises administering an  
effective amount of the compound of claim 8 to a subject in need thereof ~~human being or an  
animal.~~

Claim 32 (Currently Amended): A commercial package comprising:  
the pharmaceutical composition of claim 27 and  
a written matter associated therewith, the written matter stating that the  
pharmaceutical composition may or should be used for treating or preventing an  
inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia,

fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]],  
an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].

Claim 33 (Currently Amended): A composition comprising the compound of claim 10 in an amount sufficient to inhibit histone deacetylase inhibitor comprising the compound of claim 10.

Claim 34 (Currently Amended): A pharmaceutical composition comprising the compound of claim 10 in an amount effective for treating or preventing an inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]], an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]], which comprises the compound of claim 10.

Claim 35 (Currently Amended): A pharmaceutical composition ~~containing~~  
comprising:

the compound of claim 10 as an active ingredient, in association with  
a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 36 (Currently Amended): The composition of claim 33 in a form suitable for intravenous or intramuscular administration ~~compound of claim 10 for use as a medicament.~~

Claim 37 (Withdrawn): A method for inhibiting histone deacetylase, comprising using the compound of claim 10.

Claim 38 (Withdrawn): A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises administering an effective amount of the compound of claim 10 to a human being or an animal.

Claim 39 (Currently Amended): A commercial package comprising:  
the pharmaceutical composition of claim 34, and  
a written matter associated therewith, the written matter stating that the  
pharmaceutical composition may or should be used for treating or preventing an  
inflammatory disorder[[s]], diabetes, diabetic complications, homozygous thalassemia,  
fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), an organ transplant rejection[[s]],  
an autoimmune disease[[s]], a protozoal infection[[s]] or a tumor[[s]].